• Dabigatran Etexilate: Oral Direct Thrombin Inhibition

  2026-08-30

  The 2011 review by Blommel and Blommel presents dabigatran etexilate as the first oral direct thrombin inhibitor marketed in the United States, emphasizing its reversible thrombin inhibition, predictable anticoagulant activity, and clinical use across thromboembolic disorders. Its practical significance lies in linking prodrug pharmacology with evidence for venous thromboembolism prevention, stroke prevention in atrial fibrillation, safety assessment, and renal function–guided use.

• Sodium Phosphate Dibasic for Aquatic Assays

  2026-08-29

  Learn how Sodium phosphate dibasic supports controlled pH, matrix consistency, and reproducible aquatic toxicity workflows. This guide translates multispecies sulfamonomethoxine findings into practical buffer selection, preparation, validation, and troubleshooting decisions.

• Exemestane: From Enzyme Mechanism to Translation

  2026-08-29

  A translational perspective on Exemestane as a steroidal aromatase inhibitor, linking irreversible enzyme inactivation to experimental design, biomarker strategy, and hormone-dependent breast cancer research.

• Tamsulosin for Ureteral Stone Passage: Meta-Analysis

  2026-08-28

  This systematic review and meta-analysis addressed conflicting clinical trial results on whether tamsulosin improves spontaneous passage of symptomatic ureteral stones. Across 49 studies and 6,436 patients, the pooled evidence indicated higher expulsion rates and shorter passage times without a significant difference in overall adverse effects, while stone size and clinical context remained important for interpretation.

• EZ Cap™ Cy5 EGFP mRNA (5-moUTP) for Assays

  2026-08-28

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) enables paired measurement of mRNA uptake and EGFP translation. This guide shows how to interpret dual fluorescence using delivery biology, nanoparticle optimization, and practical assay controls.

• Anti-ROR1 Antibody: Applied Research Workflows

  2026-08-27

  Use Anti-ROR1 Antibody (Zilovertamab) to connect ROR1 binding, Wnt5a pathway assays, flow cytometry, and translational cancer models in one practical workflow. This guide also explains how to explore ROR1 biology alongside deoxynivalenol-induced liver injury without overstating evidence.

• (S)-(+)-Dimethindene maleate: M2 Research Guide

  2026-08-27

  This guide explains how (S)-(+)-Dimethindene maleate (SKU B6734) can be used as a research antagonist for experiments involving muscarinic M2 and histamine H1 receptors, with practical attention to preparation, storage, and assay interpretation. No directly matched paper evidence is supplied here, so the compound should be used in controlled exploratory workflows rather than diagnostic, therapeutic, or clinical applications.

• SARS-CoV-2 NSP15 Inhibitor Screening: Key Findings

  2026-08-26

  The 2021 reference study used structure-based virtual screening and molecular dynamics simulations to prioritize natural products against the SARS-CoV-2 NSP15 endoribonuclease. Thymopentin and oleuropein produced the strongest computational profiles, but their antiviral activity still requires biochemical, cellular, and in vivo validation.

• Cisplatin A8321: Reliable Cytotoxicity Workflows

  2026-08-26

  This scenario-based guide explains how Cisplatin (SKU A8321) can improve planning, interpretation, and handling in cell viability, proliferation, and apoptosis experiments. It combines product-specific formulation guidance with findings from a 2024 triple-negative breast cancer study to support reproducible cancer research and chemotherapy resistance studies.

• Leptin (116-130), amide, mouse in Immunometabolism

  2026-08-25

  Leptin (116-130), amide, mouse provides a defined peptide perturbation for studying energy homeostasis, leptin resistance, and immunometabolic signaling. This guide connects fragment-based assay design with pathway-causal lessons from recent SIRT6–AMPK–NLRP3 research.

• Cisplatin and ZNF263: A Translational Resistance Map

  2026-08-25

  Cisplatin remains a powerful model for connecting DNA crosslinking, apoptosis, oxidative stress, and treatment resistance. This thought-leadership guide uses recent ZNF263–STAT3 findings in colorectal cancer to propose a rigorous framework for testing CDDP sensitivity without overstating what current evidence proves.

• Cichoric Acid Targets HIF-1α in Septic AKI

  2026-08-24

  The reference study identifies a metabolic–inflammatory mechanism in which cichoric acid protects against LPS-induced acute kidney injury by restraining HIF-1α-associated glycolysis, succinate dehydrogenase activity, and NLRP3 inflammasome activation. Its combination of macrophage, metabolic, mitochondrial, and mouse renal analyses provides a useful framework for studying how immune-cell polarization contributes to septic organ damage.

• FAT4 Loss, PI3K/AKT, and Ferroptosis in HCC

  2026-08-23

  A 2026 study identifies FAT4 loss as a determinant of ferroptosis resistance and sorafenib response in hepatocellular carcinoma. The work connects FAT4 deficiency with PI3K/AKT activation and increased GPX4 and SLC7A11, suggesting a biomarker-guided strategy for studying treatment resistance.

• Degarelix acetate: GnRH Receptor Assay Guide

  2026-08-22

  Degarelix acetate enables rapid, selective suppression of GnRH-receptor signaling for receptor pharmacology, pituitary hormone regulation, and prostate cancer research. This practical guide connects concentration selection, longitudinal hormone measurements, and tissue-level endpoints with troubleshooting strategies for more reproducible endocrine assays.

• Luminescent ATP Detection Assay Kit Workflow

  2026-08-21

  Turn ATP measurements into a practical readout of cellular stress, mitochondrial dysfunction, and tissue injury. This workflow shows how the Luminescent ATP Detection Assay Kit supports reproducible cellular ATP quantification while preserving lysates for protein-based follow-up experiments.

447 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page